John De Vos

@jdevos.bsky.social

340 followers 380 following 240 posts

#StemCells Researcher | Director of the Cell Processing Facility
University of Montpellier - CHU of Montpellier | #StemCells #iPScells for #lung #CellTherapy |
Stem Genomics co-founder | President of the FSSCR

Videos

Biology 37%

Environmental science 10%

Posts Replies Media Videos

Reposted by Stefan Rahmstorf, John De Vos, Du Toit , and 4 more Stefan Rahmstorf, John De Vos, Du Toit, David Johnson, Rupert Read, Adrian Vickers, John H. Knox

Zack Labe @zacklabe.com · 1d

2025 was the hottest year on record for ocean heat content. Unfortunately, we now say this every year. 🥹

"In addition to setting a new record in 2025, the global
ocean continues to show sustained and intensified warming."

+ #OpenAccess Study: doi.org/10.1007/s003...
+ Data: www.ocean.iap.ac.cn

Bar graph showing global ocean heat content change in the upper 2000 m from the late 1950s through 2025. There is a long-term warming in the time series, which is using IAP/CAS data.

John De Vos @jdevos.bsky.social · 2d

Other data regarding #CARTCell treatments in France. Interesting!

Source : buff.ly/k3Z9kDv

John De Vos @jdevos.bsky.social · 3d

Number of #CARTCell treatments in France : rapidly increasing.

Source : buff.ly/k3Z9kDv

John De Vos @jdevos.bsky.social · 3d

Solid tumor, allogeneic #CART alert 📣 : encouraging results from a phase I study using allogeneic IL-13Rα2 CAR-T cells in five people with recurrent high-grade glioma.

buff.ly/Q8RBlx4

News: Off-the-shelf CRISPR CAR-T tackles brain tumours - CRISPR Medicine

A first-in-human, phase I trial tested intrathecal delivery of CRISPR-Cas9-edited, allogeneic IL-13Rα2 CAR-T cells in five people with recurrent high-grade glioma. The single-centre study reports…

crisprmedicinenews.com

John De Vos @jdevos.bsky.social · 6d

Allogeneic #CARTCells in phase Ib/II clinical trials in China for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL). Phase I study showed interesting results.

buff.ly/SKuRXC9

CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

SHANGHAI,Dec. 28, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted

news.futunn.com

Reposted by John De Vos

John De Vos @jdevos.bsky.social · 8d

"There’s a good likelihood that by 2050, all scientific research will be done
by superintelligent AI rather than human researchers,” Bostrom said in an e-mail. “Some humans might do science as a hobby, but they wouldn’t be making any useful contributions.”

The science of 2025

buff.ly/nElWVRL

Science in 2050: the future breakthroughs that will shape our world — and beyond

Nuclear fusion. People on Mars. Artificial general intelligence. These are just some of the advances that could come by the mid-century mark.

www.nature.com

John De Vos @jdevos.bsky.social · 8d

Monkey pluripotent stem cells-derived blastoids mature in vitro in 3D into Carnegie stage 8-9 (late gastrulation) embryos. Spectacular progress to study primate embryonic development.
buff.ly/IiFHeNU

Modelling late gastrulation in stem cell-derived monkey embryo models - Nature

An optimized 3D culture system enabled a stem cell-derived monkey blastoid to develop to day 25, recapitulating key events of primate late gastrula and demonstrating notable similarity to natural…

www.nature.com

Reposted by John De Vos

John De Vos @jdevos.bsky.social · 18d

A phase II trial using #CART cells against a solid tumor (glioblastoma).
T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic B7-H3–targeted CAR-T therapy, MT027, has received FDA IND clearance.
buff.ly/wiGPeyR

Reposted by John De Vos

John De Vos @jdevos.bsky.social · 18d

Modeling human embryo implantation in vitro: building a receptive endometrium and its interaction with blastoids (“synthetic embryos”). A remarkable achievement!
buff.ly/eZtS5NG